News – Page 940 – Endpoints News

Hit by setbacks, Lundbeck's Deborah Dunsire inks a $400M cannabinoid buyout, adding a discovery site

7 years ago

New Zolgensma data suggest comparable efficacy to Spinraza — analysts

7 years ago

Cytokinetics' comeback attempt with second-gen muscle drug is slammed by a PhII failure in ALS

7 years ago

Pioneering mRNA CEO Stéphane Bancel bags an eye-popping $58M compensation deal in wake of record IPO

7 years ago

Vendu! Weeks after Sanofi cuts ties to Alnylam, the pharma giant offloads $842M of its stock

7 years ago

The (corrected) list of the world's top 20 pharma companies

7 years ago

Genkyotex picks out silver linings from failed PhII, braces for pivotal study in primary biliary cholangitis

7 years ago

FDA rejects Acacia's lead drug — again — due to the same manufacturing issue

7 years ago

FDA expands approval of Agios' Tibsovo; AstraZeneca's long-acting diabetes drug secures US nod

7 years ago

Microcap biotech VistaGen turned to pennystock after PhII results show its depression drug doesn't work solo

7 years ago

As backlash mounts in the wake of a disastrous PhIII flop, Eisai goes deeper with 2 new hires

7 years ago

Peer Review: Anil Singhal assumes leadership of Adicet Bio; Adaptive Biotech woos Genentech vet as CMO

7 years ago

Did a disaster crush your stock in 2018? These biotechs were happy to come up with some rich compensation deals for ...

7 years ago

Insys founder, former execs face decades in jail after being found guilty in landmark opioid case

7 years ago

Woodcock details upcoming changes to NDA and BLA review process

7 years ago

Dan O’Day’s to-do list for Gilead: Recruit a Kite CEO, press the pedal on next-gen cell therapies and start ...

7 years ago

Tessa showcases preclinical promise of 'all-in-one' add-on to its cancer cell therapy, in march to the clinic

7 years ago

Weeks after a Pfizer/Merck KGaA breakdown, Clovis gambles on a $175M loan to finish a global PhIII PARP/PD-1 combo ...

7 years ago

Celgene partners on Phase 0 cancer drug studies; FDA lifts clinical hold on Xencor's bispecific

7 years ago

AstraZeneca bets cautiously on oncolytic virus discovery program, outlining $13M deal with Transgene

7 years ago

Going global, Takeda opens up 165,000-square-foot R&D facility in San Diego

7 years ago

Terry Rosen is looking to leave the thundering herd and blaze a new trail in PD-1 R&D

7 years ago

Sanofi's controversial dengue vaccine wins FDA approval, with a raft of caveats

7 years ago

The BCMA frenzy: Tracking the 37 drugs around the world racing to overtake bluebird bio and Celgene

7 years ago

First page Previous page 937 938 939940941 942 943 Next page Last page